...
首页> 外文期刊>Biochemical and Biophysical Research Communications >High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
【24h】

High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1

机译:针对高致病性禽流感病毒H5N1的稳定的基于Vero细胞的候选疫苗的高产量生产

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Highly pathogenic avian influenza (HPAI) viruses pose a global pandemic threat, for which rapid large-scale vaccine production technology is critical for prevention and control. Because chickens are highly susceptible to HPAI viruses, the supply of chicken embryos for vaccine production might be depleted during a virus outbreak. Therefore, developing HPAI virus vaccines using other technologies is critical. Meeting vaccine demand using the Vero cell-based fermentation process has been hindered by low stability and yield. In this study, a Vero cell-based HPAI H5N1 vaccine candidate (H5N1/YNVa) with stable high yield was achieved by reassortment of the Vero-adapted (Va) high growth A/Yunnan/1/2005(H3N2) (YNVa) virus with the A/Anhui/1/2005(H5N1) attenuated influenza vaccine strain (H5N1delta) using the 6/2 method. The reassorted H5N1/YNVa vaccine maintained a high hemagglutination (HA) titer of 1024. Furthermore, H5N1/YNVa displayed low pathogenicity and uniform immunogenicity compared to that of the parent virus.
机译:高致病性禽流感(HPAI)病毒构成了全球大流行威胁,为此,快速大规模的疫苗生产技术对于预防和控制至关重要。由于鸡对HPAI病毒高度敏感,因此在病毒爆发期间可能会耗尽用于疫苗生产的鸡胚供应。因此,使用其他技术开发HPAI病毒疫苗至关重要。低稳定性和低产量阻碍了使用基于Vero细胞的发酵工艺满足疫苗需求。在这项研究中,通过重新分配适应Vero的(Va)高生长A / Yunnan / 1/2005(H3N2)(YNVa)病毒,实现了具有稳定高产量的基于Vero细胞的HPAI H5N1候选疫苗(H5N1 / YNVa)使用6/2方法使用A / Anhui / 1/2005(H5N1)减毒流感疫苗株(H5N1delta)。重新分类的H5N1 / YNVa疫苗保持了1024的高血凝(HA)滴度。此外,与亲本病毒相比,H5N1 / YNVa的致病性和免疫原性低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号